Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-24-255248
Filing Date
2024-11-12
Accepted
2024-11-12 09:07:06
Documents
66
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d895663d10q.htm   iXBRL 10-Q 1245135
2 EX-31.1 d895663dex311.htm EX-31.1 6523
3 EX-31.2 d895663dex312.htm EX-31.2 6514
4 EX-32.1 d895663dex321.htm EX-32.1 3206
5 EX-32.2 d895663dex322.htm EX-32.2 3197
  Complete submission text file 0001193125-24-255248.txt   5728245

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vinc-20240930.xsd EX-101.SCH 37672
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vinc-20240930_cal.xml EX-101.CAL 33039
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20240930_def.xml EX-101.DEF 227178
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20240930_lab.xml EX-101.LAB 359322
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20240930_pre.xml EX-101.PRE 315321
69 EXTRACTED XBRL INSTANCE DOCUMENT d895663d10q_htm.xml XML 798710
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 241443995
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)